Therapeutic Drug Monitoring vs Standard Therapy during Infliximab Induction in Patients with Chronic Immune-Mediated Inflammatory Diseases

Konstantinos Papamichail; Marla C. Dubinsky; Adam S. Cheifetz

doi:10.1001/jama.2021.11477

Therapeutic Drug Monitoring vs Standard Therapy during Infliximab Induction in Patients with Chronic Immune-Mediated Inflammatory Diseases

Konstantinos Papamichail, Marla C. Dubinsky, Adam S. Cheifetz

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	1067-1068
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	326
Issue number	11
DOIs	https://doi.org/10.1001/jama.2021.11477
State	Published - 21 Sep 2021

Access to Document

10.1001/jama.2021.11477

Cite this

@article{ca204107400d47ae9eb69fe7e5b0f636,

title = "Therapeutic Drug Monitoring vs Standard Therapy during Infliximab Induction in Patients with Chronic Immune-Mediated Inflammatory Diseases",

author = "Konstantinos Papamichail and Dubinsky, {Marla C.} and Cheifetz, {Adam S.}",

note = "Funding Information: fees from Sanofi-Pasteur and Seqirus, research funding from Pfizer and AstraZeneca for unrelated studies, and grants from MedImmune. No other disclosures were reported. Funding Information: Funding/Support: This study was funded by grant U01AI144616-02S1 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. The funds were used for salary support for staff and materials to conduct the study.",

year = "2021",

month = sep,

day = "21",

doi = "10.1001/jama.2021.11477",

language = "English",

volume = "326",

pages = "1067--1068",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "11",

}

Therapeutic Drug Monitoring vs Standard Therapy during Infliximab Induction in Patients with Chronic Immune-Mediated Inflammatory Diseases. / Papamichail, Konstantinos; Dubinsky, Marla C.; Cheifetz, Adam S.
In: JAMA - Journal of the American Medical Association, Vol. 326, No. 11, 21.09.2021, p. 1067-1068.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Therapeutic Drug Monitoring vs Standard Therapy during Infliximab Induction in Patients with Chronic Immune-Mediated Inflammatory Diseases

AU - Papamichail, Konstantinos

AU - Dubinsky, Marla C.

AU - Cheifetz, Adam S.

N1 - Funding Information: fees from Sanofi-Pasteur and Seqirus, research funding from Pfizer and AstraZeneca for unrelated studies, and grants from MedImmune. No other disclosures were reported. Funding Information: Funding/Support: This study was funded by grant U01AI144616-02S1 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. The funds were used for salary support for staff and materials to conduct the study.

PY - 2021/9/21

Y1 - 2021/9/21

UR - http://www.scopus.com/inward/record.url?scp=85115397513&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.11477

DO - 10.1001/jama.2021.11477

M3 - Letter

C2 - 34546306

AN - SCOPUS:85115397513

SN - 0098-7484

VL - 326

SP - 1067

EP - 1068

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 11

ER -